In vitro activity of DS-2969b and comparator antimicrobial agents against Clostridioides (Clostridium) difficile, methicillin-resistant Staphylococcus aureus, and other anaerobic bacteria.

Published on Dec 1, 2018in Anaerobe3.331
· DOI :10.1016/J.ANAEROBE.2018.04.010
Kerin Tyrrell10
Estimated H-index: 10
Diane M. Citron57
Estimated H-index: 57
+ 2 AuthorsEllie J. C. Goldstein66
Estimated H-index: 66
Abstract The in vitro activity of DS-2969b, a novel GyrB inhibitor, and six comparator agents was studied against 101 recent North American Clostridioides difficile isolates, 46 other intestinal anaerobes and 51 strains of methicillin-resistant Staphylococcus aureus. The MIC ranges (MIC90s) of DS-2969b against C. difficile and S. aureus were 0.03–0.125 (0.125) μg/ml and 0.125–1 (0.5) μg/ml, respectively. DS-2969b showed the greatest activity of the agents tested. There was no difference in MICs of DS-2969b among different ribotypes.
📖 Papers frequently viewed together
#1Sara GomezH-Index: 1
#2Fernando ChavesH-Index: 33
Last. M. Angeles OrellanaH-Index: 7
view all 3 authors...
Abstract Recurrent diarrhea is a common complication of Clostridium difficile infection (CDI). Recurrent CDI (r-CDI) may be produced by the persistence of spores (relapse) or by the acquisition of a new strain (reinfection). In this study, we analyze epidemiological, clinical, microbiological and laboratory data from patients with r-CDI, relapse, and reinfection-CDI over 5 years and compared with a control group (non r-CDI). Among 60 patients with r-CDI, 36 patients had stool samples collected f...
#1Paul A. Lawson (OU: University of Oklahoma)H-Index: 58
#2Diane M. CitronH-Index: 57
Last. Sydney M. Finegold (UCLA: University of California, Los Angeles)H-Index: 90
view all 4 authors...
Abstract The recent proposal by Lawson and Rainey (2015) to restrict the genus Clostridium to Clostridium butyricum and related species has ramifications for the members of the genera that fall outside this clade that should not be considered as Clostridium sensu stricto . One such organism of profound medical importance is C. difficile that is a major cause of hospital-acquired diarrhea and mortality in individuals. Based on 16S rRNA gene sequence analysis, the closest relative of Clostridium d...
#1Kerin L. TyrrellH-Index: 27
#2Yumi A. WarrenH-Index: 25
Last. Ellie J. C. Goldstein (UCLA: University of California, Los Angeles)H-Index: 66
view all 4 authors...
Abstract Alistipes (previously Bacteroides) are strictly anaerobic gram-negative rods that resemble the Bacteroides fragilis group in that most species are bile-resistant and indole-positive; however, they are only weakly saccharolytic and most species produce light brown pigment only on laked rabbit blood agar. In this retrospective study, we re-identified 18 organisms previously identified phenotypically as “Bacteroides putredinis-like”, but that did not produce pigment on routine media. The s...
#1Mary Jane. FerraroH-Index: 1
#1Vera L. SutterH-Index: 17
#2Diane M. CitronH-Index: 11
Last. Sydney M. FinegoldH-Index: 4
view all 3 authors...
Cited By5
#1Ravina KullarH-Index: 22
#2Mai-Chi N Tran (SC: University of Southern California)H-Index: 1
Last. Ellie J. C. GoldsteinH-Index: 66
view all 3 authors...
Clostridioides difficile infection (CDI) is a major cause of nosocomial diarrhea that is deemed a global health threat. C. difficile strain BI/NAP1/027 has contributed to the increase in the mortality, severity of CDI outbreaks and recurrence rates (rCDI). Updated CDI treatment guidelines suggest vancomycin and fidaxomicin as initial first-line therapies that have initial clinical cure rates of over 80%. Unacceptably high recurrence rates of 15-30% in patients for the first episode and 40% for t...
#1Travis J Carlson (High Point University)H-Index: 6
#2Anne J Gonzales-Luna (UH: University of Houston)H-Index: 6
Clostridioides difficile infection (CDI) represents a major burden on the U.S. healthcare system. Despite the U.S. Food and Drug Administration (FDA) approval of fidaxomicin in 2011, observed rates of clinical cure and CDI recurrence suggest there is room to improve. As a result, there are many antibiotic treatments in the developmental pipeline for CDI. The purpose of this focused review is to summarize these antibiotic therapies in all stages of development. Here, we discuss 10 antibiotics in ...
#1Uchini S. Kosgodage (London Metropolitan University)H-Index: 9
#2Paul Matewele (London Metropolitan University)H-Index: 3
Last. Jameel M. Inal (University of Hertfordshire)H-Index: 30
view all 9 authors...
Outer membrane and membrane vesicles (OMV/MV) are released from bacteria and participate in cell communication, biofilm formation and host-pathogen interactions. Peptidylarginine deiminases (PADs) are phylogenetically conserved enzymes that catalyze post-translational deimination/citrullination of proteins, causing structural and functional changes in target proteins. PADs also play major roles in the regulation of eukaryotic extracellular vesicle release. Here we show phylogenetically conserved...
#1Vo Van Giau (Gachon University)H-Index: 16
#2Hyon Lee (Gachon University)H-Index: 16
Last. John Hulme (Gachon University)H-Index: 16
view all 4 authors...
: Clostridium difficile (C. difficile) is rapidly becoming one of the most prevalent health care-associated bacterial infections in the developed world. The emergence of new, more virulent strains has led to greater morbidity and resistance to standard therapies. The bacterium is readily transmitted between people where it can asymptomatically colonize the gut environment, and clinical manifestations ranging from frequent watery diarrhea to toxic megacolon can arise depending on the age of the i...
#1Mai-Chi N Tran (St. John's University)H-Index: 4
#2Ravina KullarH-Index: 22
Last. Ellie J. C. Goldstein (UCLA: University of California, Los Angeles)H-Index: 66
view all 3 authors...
ABSTRACTIntroduction: Clostridioides (Clostridium) difficile Infection (CDI) is an urgent global threat causing ~500,000 infections annually in the United States of America (USA) and is associated ...
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.